Stem-Cell Wonderland
By Ralph Brave,
Sacramento News & Review
| 10. 20. 2005
Will cures be affordable to all?
Last week, a middle-aged woman from Maryland sat in the Denver airport, reading a story in The New York Times headlined "California Maps Strategy for Its $3 Billion Stem Cell Project." Asked whether she's professionally involved in the life sciences, she said, "No." Why then was she reading this particular article? Without hesitation she replied, "My father died from Parkinson's disease."
So it is around the state, the nation and even the globe: Having launched a major stem-cell venture nearly a year ago, California is being watched and looked to for stem-cell cures for all kinds of chronic diseases and conditions.
But the woman in the airport would not have been encouraged by the tale told in the most recent University of California, Berkeley, alumni magazine of a woman near her own age suffering from Parkinson's. This woman's husband happens to be both a cell biologist and director of Berkeley's stem-cell center. When it comes to the prospect of a stem-cell therapy to save his wife or any other Parkinson's patient, he states his scientific opinion succinctly: "Right now, it's...
Related Articles
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ewan Bolton, The Telegraph | 11.12.2024
Fertility agencies offering embryo selection for IVF and surrogacy have been accused of promoting eugenics and misleading consumers about the power of genetic screening.
Some American clinics claim they can “rank” embryos for IVF using Preimplantation Genetic Testing for Polygenic...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first...